LVTX LAVA Therapeutics N.V.
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
LAVA-206x207
Castration-resistant prostate cancer
|
Phase 1
Phase 1
|
Phase 1/2 trial to commence 2H 2021.
|
|
LAVA-051
CD1d-expressing hematologic cancers
|
Phase 1/2
Phase 1/2
|
Phase 1/2 trial to commence 1H 2021.
|
Latest News
-
View Full Article Hide Full Article
UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCEs) to transform cancer therapy, today announced that Karen J. Wilson has been appointed to its Board of Directors and as chair of its Audit Committee. Ms. Wilson brings more than three decades of finance and leadership experience in the life sciences industry.
"I am delighted to welcome Karen to our Board of Directors," said Stephen Hurly, Chief Executive Officer and President. "She joins us at an exciting time for our company as our first gamma-delta bsTCE candidates progress towards the clinic. Her deep experience leading finance organizations across both clinical- and commercial-stage public life science companies will be invaluable to LAVA as we advance our pipeline aimed at improving patient outcomes and creating value for our shareholders."
Ms. Wilson is a biopharmaceutical finance executive and board member with experience in life science companies across finance, strategy, and risk management. She currently serves on the Board of Directors of Angion Biomedica, Connect Biopharma, and Vaxart, Inc. She was most recently Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.
"With two candidates expected to enter the clinic in 2021 following a successful IPO, I am thrilled to join LAVA's Board," Ms. Wilson said. "I am very excited about the potential of the LAVA platform to potentially transform the cancer treatment landscape. I look forward to working with the rest of the Board and management team to build on LAVA's success and optimize the value of its unique gamma-delta T cell engager platform in oncology."
About LAVA
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The company's innovative approach leverages bispecific antibodies to activate Vγ9Vδ2 T cells upon binding to membrane-expressed tumor associated antigens. Activated Vγ9Vδ2 T cells are engaged for direct, selective tumor cell killing. The company's lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.
LAVA's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect of the company's anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as "anticipate," "believe," "could," "expect," "should," "plan," "intend," "estimate," "potential" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for LAVA's product candidates, and the potential use of our product candidates to treat various tumor targets. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical trials, changes in expected or existing competition, changes in the regulatory environment, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity, failure of LAVA's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, among others. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact
Keely Zipp
-
View Full Article Hide Full Article
UTRECHT, The Netherlands, March 25, 2021 (GLOBE NEWSWIRE) -- Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, today announced that its portfolio company, LAVA Therapeutics (NASDAQ:LVTX), has successfully achieved pricing of its Nasdaq initial public offering (IPO), expected to result in gross proceeds of approximately $100 million. LVTX shares are expected to begin trading on March 25, 2021.
LAVA is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
Gilde Healthcare has played an active role in LAVA's maturation as it progressed to its IPO. Gilde Healthcare acted as the lead investor in the first institutional investment round of €16M in LAVA in 2018 and has been the only Dutch institutional shareholder to date. Additionally, Gilde Healthcare's Operational Partner Prof. Dr. Paul Parren is Executive Vice President and Head of R&D of LAVA. Gilde Healthcare also has been instrumental in relocating LAVA´s headquarters and labs to the Utrecht Science Park, establishing a US subsidiary, hiring key management and taking part in the $83 million Series C financing together with other leading investors.
Stefan Luzi, Partner at Gilde Healthcare and Member of the LAVA Board of Directors, commented: "We are proud to have been purposefully involved in the growth of LAVA from its first institutional investment round to its NASDAQ IPO in just 3 years. LAVA represents a clear case study in how we can contribute, above and beyond providing financial resources, and will serve as a model, which we aim to replicate for other differentiated healthcare companies."
Gilde Healthcare is a specialized healthcare investor with $1.8 billion under management across two fund strategies: Venture & Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States).
Gilde Healthcare Venture & Growth invests in innovative companies active in (Bio)Pharmaceuticals, HealthTech and MedTech. The portfolio of the Venture & Growth fund is balanced with fast growing life science companies from Europe and North America.
For more information, please visit www.gildehealthcare.com.
Investor & Media Contact
Chris Maggos
LifeSci Advisors
+41 79 367 6254
[email protected]